Immunomedics, Inc. (IMMU) and UCB SA Announce Restructuring of Epratuzumab License Agreement for Up to $60 Million
12/28/2011 7:49:24 AM
More...
|
UCB SA Release; Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
12/5/2011 12:34:12 PM
More...
|
UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million
6/9/2011 10:24:03 AM
More...
|
UCB SA Plans EUR250M ($334M) Plant To Meet Cimzia Demand
1/3/2011 11:44:01 AM
More...
|
Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M
7/30/2010 7:25:22 AM
More...
|
UCB SA And Immunomedics, Inc. (IMMU) Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
6/16/2010 8:34:52 AM
More...
|
UCB SA Subsidiary, Schwarz Pharma, To Pay $22M In False Claims Settlement
4/30/2010 8:17:37 AM
More...
|
Interim Report - Promising Early Results for UCB SA's New Products
10/22/2009 10:30:05 AM
More...
|
FDA: Johnson & Johnson (JNJ) (JOBS), Abbott Laboratories (ABT) (JOBS), Amgen (AMGN) (JOBS), UCB SA, and Wyeth (WYE) (JOBS) Arthritis Drugs Raise Cancer Risk in Kids
8/4/2009 12:27:14 PM
More...
|